Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Commissioner-designate Jane Henney signals continuity in centers management.

This article was originally published in The Tan Sheet

Executive Summary

FDA COMMISSIONER NOMINEE HENNEY SIGNALS CONTINUITY, suggesting there will be stability in top-side agency support for the agency's six operating centers. Jane Henney, MD, lists recruiting five of the six center directors among her major accomplishments during her first tour of duty at FDA as deputy commissioner for operations from 1992-1994. The physician directors of the Centers for Drug Evaluation & Research (Janet Woodcock), Biologics Evaluation & Research (Kathryn Zoon) and Devices & Radiologic Health (Bruce Burlington) all were appointed to their positions during Henney's tenure.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088581

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel